Targeting Hemoglobin to Reduce Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Authors

Hussein A Zeineddine
Pedram Honarpisheh
Devin McBride
Peeyush Kumar Thankamani Pandit
Ari Dienel
Sung-Ha Hong
James Grotta
Spiros Blackburn

Publication Date

10-1-2022

Journal

Translational Stroke Research

Abstract

Delayed cerebral ischemia (DCI) continues to be a sequela of aneurysmal subarachnoid hemorrhage (aSAH) that carries significant morbidity and mortality. Aside from nimodipine, no therapeutic agents are available to reduce the incidence of DCI. Pathophysiologic mechanisms contributing to DCI are poorly understood, but accumulating evidence over the years implicates several factors. Those have included microvessel vasoconstriction, microthrombosis, oxidative tissue damage, and cortical spreading depolarization as well as large vessel vasospasm. Common to these processes is red blood cell leakage into the cerebrospinal fluids (CSF) and subsequent lysis which releases hemoglobin, a central instigator in these events. This has led to the hypothesis that early blood removal may improve clinical outcome and reduce DCI. This paper will provide a narrative review of the evidence of hemoglobin as an instigator of DCI. It will also elaborate on available human data that discuss blood clearance and CSF drainage as a treatment of DCI. Finally, we will address a recent novel device that is currently being tested, the Neurapheresis CSF Management System™. This is an automated dual-lumen lumbar drainage system that has an option to filter CSF and return it to the patient.

Keywords

Brain Ischemia, Cerebral Infarction, Hemoglobins, Humans, Incidence, Subarachnoid Hemorrhage, Vasospasm, Intracranial, Cerebrospinal fluid filtration, subarachnoid hemorrhage, vasospasm, delayed cerebral ischemia

Comments

Data Availability Statement

PMID: 35157256